Ibandronsäure Ratiopharm

Active Ingredient:: Ibandronic Acid
Origin:: EU

Ibandronsäure Ratiopharm (Ibandronic Acid)

Q: What conditions is Ibandronsäure Ratiopharm used for?

Ibandronsäure Ratiopharm is used to treat osteoporosis, including postmenopausal and glucocorticoid‑induced forms, as well as Paget's disease of bone. In these conditions it helps reduce bone loss, increase bone mineral density, and lower the risk of fractures or abnormal bone remodeling.

Q: How does Ibandronic Acid work in the body?

Ibandronic Acid binds to hydroxyapatite at sites of active bone turnover. When osteoclasts attach to these crystals, the drug is taken up and blocks the mevalonate pathway, preventing prenylation of essential proteins. This impairs osteoclast activity, reduces bone resorption, and allows bone formation to predominate.

Q: What is the usual dose of Ibandronsäure Ratiopharm?

The specific dose and infusion schedule are determined by the prescribing clinician based on the patient’s indication, renal function, and overall health status. Healthcare professionals follow the product’s prescribing information to select the appropriate regimen.

Q: Is Ibandronsäure Ratiopharm safe during pregnancy or breastfeeding?

Ibandronsäure Ratiopharm is generally contraindicated in pregnancy and lactation because safety data are lacking and potential risks to the fetus or infant exist. It should only be used if the potential benefit justifies the risk, and this decision must be made by a qualified healthcare provider.

Q: How do I order Ibandronsäure Ratiopharm from GNH India?

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Q: How does Ibandronsäure Ratiopharm compare with other bisphosphonates?

Ibandronsäure Ratiopharm, like other bisphosphonates, inhibits osteoclast‑mediated bone resorption. Compared with oral agents such as alendronate, the intravenous route bypasses gastrointestinal absorption issues and may provide more rapid and consistent drug exposure. However, safety monitoring, especially for renal function and acute phase reactions, remains essential.

Q: What are the recommended storage conditions for Ibandronsäure Ratiopharm?

The product should be stored at 2‑8 °C in a refrigerator. Keep it in the original packaging, protect it from light, and avoid freezing or shaking the vial. Do not store at room temperature for extended periods, as stability may be compromised.

Q: How is Ibandronsäure Ratiopharm administered?

Ibandronsäure Ratiopharm is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion is typically administered over a short period, following standard aseptic techniques and monitoring for any immediate reactions during and after the infusion.

Q: What are the most serious risks associated with Ibandronsäure Ratiopharm?

Serious risks include osteonecrosis of the jaw, atypical femur fractures, severe renal impairment, and marked hypocalcaemia. Patients should be monitored for signs of jaw pain, unusual thigh or groin pain, changes in kidney function, and calcium levels, and any concerning symptoms should prompt immediate medical evaluation.

Q: Who should not receive Ibandronsäure Ratiopharm?

Patients with severe renal impairment (eGFR <30 mL/min), untreated hypocalcaemia, known hypersensitivity to ibandronate or any excipients, and those who are pregnant or breastfeeding without a clear benefit‑risk justification should not receive the product. Clinicians must assess each individual’s medical history before prescribing.

Ibandronic Acid, the active ingredient in Ibandronsäure Ratiopharm, is a bisphosphonate presented as an intravenous formulation for use in bone disease treatment. It is indicated for conditions characterised by excessive bone resorption, such as osteoporosis and Paget's disease of bone.

GNH India supplies Ibandronsäure Ratiopharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Ratiopharm Gmbh

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ibandronsäure Ratiopharm acts on disorders of bone metabolism where excessive resorption is a key feature.

Postmenopausal osteoporosis: increases bone mineral density and lowers vertebral fracture risk.
Glucocorticoid‑induced osteoporosis: reduces bone loss associated with long‑term steroid therapy.
Paget's disease of bone: normalises abnormal bone remodelling and alleviates bone pain.

How It Works

Ibandronic Acid binds selectively to hydroxyapatite crystals at sites of active bone turnover. When osteoclasts attach to these crystal surfaces, the drug is internalised, inhibiting the mevalonate pathway and disrupting prenylation of small G‑proteins. This impairs osteoclast function, leading to reduced bone resorption and a net increase in bone mass.

Side Effects

Ibandronsäure Ratiopharm may be associated with a range of adverse reactions.

Common Side Effects

Acute phase reaction: fever, chills, muscle pain.
Nausea or vomiting.
Headache.
Arthralgia.
Injection‑site discomfort.
Flu‑like symptoms.

Serious or Rare Side Effects

Osteonecrosis of the jaw.
Atypical femur fracture.
Severe renal impairment.
Marked hypocalcaemia.
Anaphylactic or severe hypersensitivity reactions.
New‑onset atrial fibrillation.

Precautions & Warnings

Before initiating therapy, several safety considerations should be addressed.

Renal function: assess creatinine clearance and avoid use in severe renal impairment.
Calcium/Vitamin D status: ensure adequate levels to prevent hypocalcaemia.
Concomitant bisphosphonate therapy: avoid duplicate treatment.
Pregnancy and lactation: contraindicated unless benefits outweigh risks.
Drug interactions: review all concomitant medicines for potential conflicts.
Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Ibandronsäure Ratiopharm can interact with several drug classes.

Major Interactions (Avoid)

Severe renal impairment (eGFR <30 mL/min): increased toxicity.
Concurrent use of other bisphosphonates: additive risk of oversuppression.
Uncorrected hypocalcaemia: may precipitate severe calcium loss.
Aminoglycoside antibiotics: heightened nephrotoxic potential.

Moderate Interactions (Monitor Closely)

NSAIDs: may further compromise renal function.
Systemic corticosteroids: increase risk of osteonecrosis of the jaw.
Loop diuretics: can alter calcium balance and require monitoring.

Frequently Asked Questions

Ibandronsäure Ratiopharm is used to treat osteoporosis, including postmenopausal and glucocorticoid‑induced forms, as well as Paget's disease of bone. In these conditions it helps reduce bone loss, increase bone mineral density, and lower the risk of fractures or abnormal bone remodeling.

Ibandronic Acid binds to hydroxyapatite at sites of active bone turnover. When osteoclasts attach to these crystals, the drug is taken up and blocks the mevalonate pathway, preventing prenylation of essential proteins. This impairs osteoclast activity, reduces bone resorption, and allows bone formation to predominate.

The specific dose and infusion schedule are determined by the prescribing clinician based on the patient’s indication, renal function, and overall health status. Healthcare professionals follow the product’s prescribing information to select the appropriate regimen.

Ibandronsäure Ratiopharm is generally contraindicated in pregnancy and lactation because safety data are lacking and potential risks to the fetus or infant exist. It should only be used if the potential benefit justifies the risk, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Ibandronsäure Ratiopharm, like other bisphosphonates, inhibits osteoclast‑mediated bone resorption. Compared with oral agents such as alendronate, the intravenous route bypasses gastrointestinal absorption issues and may provide more rapid and consistent drug exposure. However, safety monitoring, especially for renal function and acute phase reactions, remains essential.

The product should be stored at 2‑8 °C in a refrigerator. Keep it in the original packaging, protect it from light, and avoid freezing or shaking the vial. Do not store at room temperature for extended periods, as stability may be compromised.

Ibandronsäure Ratiopharm is given by intravenous infusion under the supervision of a qualified healthcare professional. The infusion is typically administered over a short period, following standard aseptic techniques and monitoring for any immediate reactions during and after the infusion.

Serious risks include osteonecrosis of the jaw, atypical femur fractures, severe renal impairment, and marked hypocalcaemia. Patients should be monitored for signs of jaw pain, unusual thigh or groin pain, changes in kidney function, and calcium levels, and any concerning symptoms should prompt immediate medical evaluation.

Patients with severe renal impairment (eGFR <30 mL/min), untreated hypocalcaemia, known hypersensitivity to ibandronate or any excipients, and those who are pregnant or breastfeeding without a clear benefit‑risk justification should not receive the product. Clinicians must assess each individual’s medical history before prescribing.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 31 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.